These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 3502781

  • 1. PUVA therapy for drug-resistant graft-versus-host disease.
    Atkinson K, Weller P, Ryman W, Biggs J.
    Bone Marrow Transplant; 1986 Dec; 1(2):227-36. PubMed ID: 3502781
    [Abstract] [Full Text] [Related]

  • 2. PUVA therapy for chronic cutaneous graft-vs-host disease.
    Jampel RM, Farmer ER, Vogelsang GB, Wingard J, Santos GW, Morison WL.
    Arch Dermatol; 1991 Nov; 127(11):1673-8. PubMed ID: 1952971
    [Abstract] [Full Text] [Related]

  • 3. [Photochemotherapy (PUVA) of acute graft-versus-host disease].
    Reinauer S, Lehmann P, Plewig G, Heyll A, Söhngen D, Hölzle E.
    Hautarzt; 1993 Nov; 44(11):708-12. PubMed ID: 8276589
    [Abstract] [Full Text] [Related]

  • 4. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA).
    Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R, Horn T.
    Bone Marrow Transplant; 1996 Jun; 17(6):1061-7. PubMed ID: 8807115
    [Abstract] [Full Text] [Related]

  • 5. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study.
    Wiesmann A, Weller A, Lischka G, Klingebiel T, Kanz L, Einsele H.
    Bone Marrow Transplant; 1999 Jan; 23(2):151-5. PubMed ID: 10197800
    [Abstract] [Full Text] [Related]

  • 6. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy.
    Hoffner MV, Carrizosa Esquivel A, Pulpillo Ruiz A, Herrera Saval A, Conejo-Mir J, Camacho FM.
    J Drugs Dermatol; 2009 Nov; 8(11):1027-9. PubMed ID: 19894371
    [Abstract] [Full Text] [Related]

  • 7. [PUVA therapy for cutaneous acute graft-versus-host disease--a case report].
    Inamitsu T, Inoue M, Akiyoshi H, Honda K, Shibuya T, Nakayama H, Ueda K.
    Rinsho Ketsueki; 1995 Nov; 36(11):1321-5. PubMed ID: 8691576
    [Abstract] [Full Text] [Related]

  • 8. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 9. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D, Martyn-Simmons CL, Osborne G, Kenyon M, Salisbury JR, Devereux S, Pagliuca A, Ho AY, Mufti GJ, du Vivier AW.
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [Abstract] [Full Text] [Related]

  • 10. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease.
    Wolff D, Anders V, Corio R, Horn T, Morison WL, Farmer E, Vogelsang GB.
    Photodermatol Photoimmunol Photomed; 2004 Aug; 20(4):184-90. PubMed ID: 15238096
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of the acute graft versus host skin reaction with cyclosporin and PUVA].
    Read D, Piérad GE, de la Brassinne M, Bury J.
    Ann Dermatol Venereol; 1988 Aug; 115(4):427-31. PubMed ID: 3046456
    [Abstract] [Full Text] [Related]

  • 12. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H, Ehninger G, Schmidt H, Berner B, Reuss-Borst M, Waller HD, Müller CA, Einsele H.
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [Abstract] [Full Text] [Related]

  • 13. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients.
    Racadot E, Milpied N, Bordigoni P, Cahn JY, Plouvier E, Lioure B, Lutz P, Wijdenes J, Herve P.
    Bone Marrow Transplant; 1995 May; 15(5):669-77. PubMed ID: 7670394
    [Abstract] [Full Text] [Related]

  • 14. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease.
    Epstein JB, Reece DE.
    Bone Marrow Transplant; 1994 Jan; 13(1):81-6. PubMed ID: 8019458
    [Abstract] [Full Text] [Related]

  • 15. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease.
    Rossetti F, Dall'Amico R, Crovetti G, Messina C, Montini G, Dini G, Locatelli F, Argiolu F, Miniero R, Zacchello G.
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():175-81. PubMed ID: 8932825
    [Abstract] [Full Text] [Related]

  • 16. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease.
    Ghoreschi K, Thomas P, Penovici M, Ullmann J, Sander CA, Ledderose G, Plewig G, Kolb HJ, Röcken M.
    Eur J Dermatol; 2008 Nov; 18(6):667-70. PubMed ID: 18955201
    [Abstract] [Full Text] [Related]

  • 17. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease.
    Eppinger T, Ehninger G, Steinert M, Niethammer D, Dopfer R.
    Transplantation; 1990 Nov; 50(5):807-11. PubMed ID: 2238056
    [Abstract] [Full Text] [Related]

  • 18. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M, Khojasteh HN, Ramzi M, Haghshenas M.
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [Abstract] [Full Text] [Related]

  • 19. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C, Stephan JL, Donadieu J, Le Deist F, Racadot E, Wijdenes J, Fischer A.
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [Abstract] [Full Text] [Related]

  • 20. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.